Dextromethorphan

Speaker 1…and this often leads us to consider treatments like dextromethorphan, an NMDA antagonist. It’s effective for pain relief, but the conversation gets interesting when we look at its long-term effects on aging and all-cause mortality.

Speaker 2Right. The problem is that chronic pain itself accelerates biological aging. We see this with conditions like painful diabetic neuropathy, which is associated with accelerated epigenetic aging and telomere shortening compared to painless neuropathy. That's from a study in *GeroScience* in 2025. So, treating pain is crucial.

Speaker 1Absolutely. The challenge is balancing that immediate benefit against potential long-term risks of the intervention. While dextromethorphan can alleviate pain, mitigating that aging acceleration, what about its direct effects on longevity markers?

Speaker 2That’s where the evidence gets a bit murky regarding dextromethorphan itself and biological aging or all-cause mortality. While its mechanism via NMDA receptors is interesting in an anti-aging context, direct evidence demonstrating improved biological aging or reduced all-cause mortality from long-term dextromethorphan use isn't established.

Speaker 1And we also need to consider potential harms. Long-term use, especially in older adults, can bring risks like falls, sedation, and cognitive changes, which themselves impact quality of life and potentially longevity, outweighing any theoretical anti-aging benefit.

Speaker 2Exactly. The benefits of appropriate, supervised dextromethorphan use for pain are clear. But for claims about slowing biological aging or reducing all-cause mortality, the evidence just isn't there yet. We still need much more research to understand that complex interplay.